| 101 |
26669450 | PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. | 2015 Dec 15 |
1 |
| 102 |
24189460 | Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. | 2014 Jan 1 |
1 |
| 103 |
24361480 | Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor. | 2014 Jan |
2 |
| 104 |
24607283 | PARP inhibitors in ovarian cancer: current status and future promise. | 2014 May |
1 |
| 105 |
24761869 | Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. | 2014 |
2 |
| 106 |
24882434 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | 2014 Jul |
1 |
| 107 |
25124282 | Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. | 2014 Dec |
1 |
| 108 |
22983827 | Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. | 2013 Jan |
2 |
| 109 |
23275151 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. | 2013 Apr |
1 |
| 110 |
23410825 | PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. | 2013 May |
5 |
| 111 |
23479135 | Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. | 2013 May |
1 |
| 112 |
23640560 | Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells. | 2013 Mar |
2 |
| 113 |
22504675 | [Clinical development of PARP inhibitors]. | 2012 Apr |
1 |
| 114 |
22869732 | BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. | 2012 Aug 21 |
2 |
| 115 |
22926640 | Clinical trials and future potential of targeted therapy for ovarian cancer. | 2012 Oct |
1 |
| 116 |
21370912 | Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. | 2011 Apr 14 |
1 |
| 117 |
21819606 | Drug therapy for hereditary cancers. | 2011 Aug 6 |
1 |
| 118 |
20406929 | Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. | 2010 May 20 |
1 |
| 119 |
20550106 | Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. | 2010 Jul 27 |
6 |
| 120 |
20940192 | Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. | 2010 Nov 20 |
1 |
| 121 |
19053130 | Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. | 2009 Jan 5 |
1 |
| 122 |
18977144 | Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. | 2008 Dec 1 |
4 |
| 123 |
17332279 | Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. | 2007 Mar 1 |
1 |
| 124 |
16787355 | Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. | 2006 Jan |
2 |
| 125 |
9380409 | The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. | 1997 Sep 25 |
1 |